Epilepsy Patient Articles & Analysis: Older
6 news found
Flowonix Medical Inc. of New Jersey, and Colorado-based Cerebral Therapeutics, announced today the first patients implanted with the Prometra II Programmable Infusion System in the Australian Direct Drug Administration for Refractory Epilepsy (ADDRESS) clinical trial at St. ...
These algorithms can be focused on therapeutic areas such as neurodegenerative disorders, epilepsy, sleep disorders and mental illness. For example, Beacon is currently assessing novel EEG signatures in Alzheimer's disease patients to identify which patients may or may not benefit from a specific type of therapy. ...
Drug-resistant epilepsy (DRE) occurs in approximately 30% of epilepsy patients, resulting in significant complications including increased risk of death, psychological disorders, and other severely debilitating conditions. ...
Food and Drug Administration (FDA) of its Investigational New Drug (IND) application to initiate its first-in-human Phase 1/2 clinical trial evaluating the safety and efficacy of NRTX-1001 in patients with drug-resistant mesial temporal lobe epilepsy (MTLE). Epilepsy is one of the most common neurological disorders affecting over three million ...
Girouard continued, “With this acquisition, Brain Sentinel can now offer a more complete line of technology for epilepsy patients--an FDA cleared, prescription diagnostic system for physician use, and now a seizure monitor for real time notification of seizure-like activity for non-prescription consumer ...
“Validation of sEMG as a useful biomarker in the monitoring of our seizure patients gives us a new tool to help patients get their seizures under control,” said Jonathan Halford, M.D., lead author of the study and Associate Professor of Neurology at the Medical University of South Carolina. ...